

## DAFTAR PUSTAKA

- Abeed, A., Jaleel, G., dan Youssef, M., 2019, Novel Heterocyclic Hybrids Based on 2-Pirazolin: Synthesis and Assessment of Anti-Inflammatory and Analgesic Activities, *Current organic synthesis*, 16(6), 921–930.
- Ajay & Murcko M., 1995, Computational methods to predict binding free energy in ligand-receptor complexes, *J. Med. Chem*, 38 (26): 4953–67.
- American Cancer Society, 2019, Cancer Statistics Center, <http://cancerstatisticscenter.cancer.org>, 22 Januari 2022.
- Bashir, R., Ovais, S., Yaseen, S., Hamid, H., Alam, S., Samim, M., Singh, S., dan Javed, K., 2011, Synthesis of some new 1,3,5-trisubstituted pirazolins bearing benzene sulfonamide as anticancer and anti-inflammatory agents, *Bioorganic & medicinal chemistry letters*, 21: 4301–5.
- Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., dan Caggiano, V., 2007, Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry, *Cancer*, 109(9), 1721–1728.
- Blows, F. M., Driver, K. E., Schmidt, M. K., Broeks, A., van Leeuwen, F. E., Wesseling, J., Cheang, M. C., Gelmon, K., Nielsen, T. O., Blomqvist, C., Heikkilä, P., Heikkinen, T., Nevanlinna, H., Akslen, L. A., Bégin, L. R., Foulkes, W. D., Couch, F. J., Wang, X., Cafourek, V., Olson, J. E., Huntsman, D., 2010, Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS medicine*, 7(5), e1000279.
- Bogdan, S. dan Klämbt, C., 2001, Epidermal growth factor receptor signaling, *Current biology : CB*, 11(8), R292–R295.
- Brabender, J., Danenberg, K. D., Metzger, R., Schneider, P. M., Park, J., Salonga, D., Hölscher, A. H., dan Danenberg, P. V., 2001, Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival, *Clinical cancer research : an official journal of the American Association for Cancer Research*, 7(7), 1850–1855.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., dan Jemal, A., 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, *CA: a cancer journal for clinicians*, 68: 394–424.
- Cai, X., Zhao, S., Cai, D., Zheng, J., Zhu, Z., Wei, D., Zheng, Z., Zhu, H., dan Chen, Y., 2019, Synthesis and evaluation of novel D-ring substituted steroidal pirazolins as potential anti-inflammatory agents, *Steroids*, 146, 70–78.
- Changavi, A.A., Shashikala, A., dan Ramji, A.S., 2015, Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas, *Journal of Laboratory Physicians*, 7: 79–83.
- Cherkasov, A., Muratov, E.N., Fourches, D., Varnek, A., Baskin, I.I., Cronin, M., Dearden, J., Gramatica, P., Martin, Y.C., Todeschini, R., Consonni, V.,

- Kuz'min, V.E., Cramer, R., Benigni, R., Yang, C., Rathman, J., Terfloth, L., Gasteiger, J., Richard, A., dan Tropsha, A., 2014, QSAR Modeling: Where Have You Been? Where Are You Going To?, *J Med Chem*, 57(12): 4977–5010.
- Chovatia, Y. S., Gandhi, S.P., Gorde, P.L., dan Bagade, S.B., 2010, Synthesis and antibacterial activity of some Pirazolin turunanives, *Oriental Journal of Chemistry*, 26: 275–278.
- Claverie, J. & Notredame, C., 2006, Bioinformatic for Dummies, 2nd edition, *Wiley Publishing Inc.*, Indiana.
- Dancey, J. dan Sausville, E.A., 2003, Issues and progress with protein kinase inhibitors for cancer treatment, *Nature Reviews, Drug Discovery*, 2: 296–313.
- Dearden, J. C., 2003, In silico prediction of drug toxicity, *Journal of Computer-Aided Molecular Design*, 17 (2-4): 119-27.
- Dowell, J., Minna, J.D., dan Kirkpatrick, P., 2005, Erlotinib hydrochloride, *Nature Reviews. Drug Discovery*, 4: 13–14.
- Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger J., dan Waterfield, M., D., 1984, Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences, *Nature*, 307, 521–527.
- Fessenden, R.J. & Fessenden, J.S., 1982, *Kimia Organik*, diterjemahkan oleh Pudjaatmaka, A. H., Edisi Ketiga, Jilid 1, 237-239, Penerbit Erlangga, Jakarta.
- Ferguson K. M., 2004, Active and inactive conformations of the epidermal growth factor receptor, *Biochemical Society transactions*, 32(Pt 5), 742–745.
- FDA, 2004, Erlotinib, [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2004/21-743\\_Tarceva.cfm](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva.cfm), 18 November 2004.
- Ferte, J., Kühnel, J. M., Chapuis, G., Rolland, Y., Lewin, G., dan Schwaller, M. A., 1999, Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure-activity relationships. *Journal of medicinal chemistry*, 42(3), 478–489.
- Flynn, J. F., Wong, C., dan Wu, J. M., 2009, Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer. *Journal of oncology*, 526963.
- Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H. J., Walker, F., Frenkel, M. J., Hoyne, P. A., Jorissen, R. N., Nice, E. C., Burgess, A. W., dan Ward, C. W., 2002, Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha, *Cell*, 110(6), 763–773.
- George, R. F., Kandeel, M., El-Ansary, D. Y., dan El Kerdawy, A. M., 2020, Some 1,3,5-trisubstituted pyrazoline derivatives targeting breast cancer: Design, synthesis, cytotoxic activity, EGFR inhibition and molecular docking, *Bioorganic Chemistry*, Volume 99, 103780, ISSN 0045-2068.
- Gomes, P., Ouro, P., Silva, A., dan Silva, V., 2020, Stiril Pyrazoles: Properties, Synthesis and Transformations. *Molecules (Basel, Switzerland)*, 25(24), 5886.

- Gotoh, N., Tojo, A., Hino, M., Yazaki, Y., dan Shibuya, M., 1992, A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor, *Biochemical and biophysical research communications*, 186(2), 768–774.
- Grandis R., J., Melhem, M.F., Barnes, E.L., dan Tweardy, D.J., 1996, Quantitative immunohistochemical analysis of transforming growth factor- $\alpha$  and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck, *Cancer*, 78: 1284–1292.
- Hsu, J. S., Huang, M. S., Chen, C. Y., Liu, G. C., Liu, T. C., Chong, I. W., Chou, S. H., dan Yang, C. J., 2014, Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma, *Journal of thoracic imaging*, 29(6), 357–363.
- Huang, L. dan Fu, L., 2015, Mechanisms of resistance to EGFR tyrosin kinase inhibitors, *Acta Pharmaceutica Sinica. B*, 5: 390–401.
- Hynes, N.E. dan Lane, H.A., 2005, ERBB receptors and cancer: the complexity of targeted inhibitors. *Nature Reviews, Cancer*, 5: 341–354.
- Jain A.N., 2006, Scoring functions for protein-ligand docking, *Current protein & peptide science*, 7(5), 407–420.
- Jaishree, D.M., Manoj, S.C., Balsere, N.G., dan Rajput, P.R. 2010, Synthesis and Study of Chlorosubstituted 4-Aroyl and 4- Alkoyl-Pirazolins, Pyrazoles and Their Effect on Some Flowering Plants, *Indian Journal of Chemistry*. 49: 505-555.
- Jo, S., Kim, T., Iyer, V.G., dan W. I., 2008, CHARMM-GUI: A Web-based Graphical User Interface for CHARMM, *J. Comput. Chem.*, 29:1859-1865.
- Kao, J., Salari, K., Bocanegra, M., Choi, Y. L., Girard, L., Gandhi, J., Kwei, K. A., Hernandez-Boussard, T., Wang, P., Gazdar, A. F., Minna, J. D., dan Pollack, J. R., 2009, Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery, *PloS one*, 4(7), e6146.
- Kemenkes RI, 2018, Kanker Payudara, <https://www.kemkes.go.id/article/view/19020100003/hari-kanker-sedunia-2019.html>, 31 Januari 2019.
- Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., dan Halmos, B., 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, *The New England journal of medicine*, 352(8), 786–792.
- Konecny, G. E., Santos, L., Winterhoff, B., Hatmal, M., Keeney, G. L., Mariani, A., Jones, M., Neuper, C., Thomas, B., Muderspach, L., Riehle, D., Wang, H. J., Dowdy, S., Podratz, K. C., dan Press, M. F., 2009, HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with non endometrioid (type II) endometrial cancer, *British journal of cancer*, 100(1), 89–95.
- Kumar, A., Varadaraj, B., dan Singla, R.K., 2013, Synthesis and evaluation of antioxidant activity of novel 3,5-disubstituted-2-pirazolins, *Bulletin of Faculty of Pharmacy, Cairo University*, 51.
- Kunal R., Supratik K., dan Rudra Narayan D., 2015, Understanding the Basics of

- QSAR for Applications in Pharmaceutical Sciences and Risk Assessment, Academic Press, *Chapter 10 - Other Related Techniques*, Pages 357-425, ISBN 9780128015056.
- Levai, A., 2002, Synthesis of 2-pyrazolines by the reactions of alpha, beta-unsaturated aldehydes, ketones, and esters with diazoalkanes, nitrile imines, and hydrazines. *Journal of heterocyclic chemistry*, 39(1), 1-14.
- Lemmon, M. A., Bu, Z., Ladbury, J. E., Zhou, M., Pinchasi, D., Lax, I., Engelman, D. M., dan Schlessinger, J., 1997, Two EGF molecules contribute additively to stabilization of the EGFR dimer, *The EMBO journal*, 16(2), 281-294.
- Marcou, G. dan Rognan, D., 2007, Optimizing fragment and scaffold docking by use of molecular interaction fingerprints, *Journal of Chemical Information and Modeling*, 47 (1), 195-207.
- Maruyama, I.N., 2014, Mechanisms of Activation of Receptor Tyrosin kinases: Monomers or Dimers, *Cells*, 3: 304-330.
- Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G.N., dan Ueno, N.T., 2012, Role of epidermal growth factor receptor in breast cancer, *Breast Cancer Research and Treatment*, 136: 331-345.
- Matiadis, D. dan Sagnou, M., 2020, Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview. *International journal of molecular sciences*, 21(15), 5507.
- Mendelsohn, J. dan Baselga, J., 2000, The EGF receptor family as targets for cancer therapy, *Oncogene*, 19: 6550-6565.
- Morgillo, F., dan Lee, H., 2005, Resistance to epidermal growth factor receptor-targeted therapy, *Drug Resist Updat* 8: 298-310, *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*. 8. 298-310.
- Naim, M., Bhat, S., Rankin, K. N., Dennis, S., Chowdhury, S. F., Siddiqi, I., Drabik, P., Sulea, T., Bayly, C. I., Jakalian, A., dan Purisima, E. O., 2007, Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space. *Journal of chemical information and modeling*, 47(1), 122-133.
- Nauduri, D. dan Reddy, G. B., 1998, Antibacterials and antimycotics: Part 1: Synthesis and activity of 2-pyrazolin turunanives, *Chemical & pharmaceutical bulletin*, 46(8), 1254-1260.
- Oda, K., Matsuoka, Y., Funahashi, A., dan Kitano, H., 2005, A comprehensive pathway map of epidermal growth factor receptor signaling, *Molecular Systems Biology*, 1: 2005.0010.
- Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J. H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., dan Yokoyama, S., 2002, Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains, *Cell*, 110(6), 775-787.
- Onitilo, A.A., Engel, J.M., Greenlee, R.T., dan Mukesh, B.N., 2009, Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival, *Clinical Medicine & Research*, 7: 4-13.
- Pebriana R. B., Romadhon A. F., Yuniarto A., Rokhman M. R., Fitriyah N. Q.,

- Jenie R. I., dan Meiyanto E., 2012, Docking Kurkumin dan Senyawa Analognya Pada Reseptor Progesteron: Studi Interaksinya Selective Progesterone Receptor Modulators (SPRMs), *PHARMACON*, Vol. 13, No. 2.
- Perou, C. M., Sørli, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., Lønning, P. E., Børresen-Dale, A. L., Brown, P. O., dan Botstein, D., 2000, Molecular portraits of human breast tumours, *Nature*, 406(6797), 747–752.
- Pranowo H.D. & Hetadi A.K.R., 2011, *Pengantar Kimia Komputasi*, Penerbit Lubuk Agung, Bandung: 1-118.
- Raghuvanshi, D.S., Verma, N., Singh, S.V., Khare, S., Pal, A., dan Negi, A.S., 2019, Synthesis of thymol-based pirazolins: An effort to perceive novel potent-antimalarials. *Bioorganic Chemistry*, 88: 102933.
- Rani, M., Yusuf, M., Khan, S.A., Sahota, P.P., dan Pandove, G., 2015, Synthesis, studies and in-vitro antibacterial activity of N-substituted 5-(furan-2-yl)-phenyl pirazolins. *Arabian Journal of Chemistry*, 8: 174–180.
- Rasyid, H., Purwono, B., dan Pranowo, H. 2020, Design of New Quinazoline Derivative as EGFR (Epidermal Growth Factor Receptor) Inhibitor through Molecular Docking and Dynamics Simulation, *Indonesian Journal of Chemistry*, 21(1), 201-211.
- Rollando. 2017, *Pengantar Kimia Medisinal*, Malang, Jawa Timur: CV. Seribu Bintang.
- Sapre, N., Gupta, S., Pancholi, N., 2008, Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzo diazepinone (TIBO) turunanives as HIV-1 NNRT inhibitors, *Journal of computer-aided molecular design*, 22. 69-80.
- Sardjiman, SS., Reksohadiprodjo, MS., Hakim, L., van der Groot, H., dan Timmerman, H., 1997, 1,5-Difenil-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents, Synthesis and structure-activity relationship, *Eur. J. Med. Chem.*, 32, 625-630.
- Seshacharyulu, P., Ponnusamy, M.P., Haridas, D., Jain, M., Ganti, A.K., dan Batra, S.K., 2012, Targeting the EGFR signaling pathway in cancer therapy, *Expert Opinion on Therapeutic Targets*, 16: 15–31.
- Sever, B., Altıntop, M. D., Radwan, M. O., Özdemir, M., Otsuka, A., Fujita, M., Ciftci, H. I., 2019, Design, synthesis and biological evaluation of a new series of thiazolyl-pirazolins as dual EGFR and HER2 inhibitors, *European Journal of Medicinal Chemistry*, 0223-5234.
- Sharma, O., Sultan, A. A., Ding, H., dan Triggle, C. R., 2020, A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. *Frontiers in immunology*, 11, 585354.
- Smith, M., March, J., & March, J., 2001, *March's advanced organic chemistry: Reactions, mechanisms, and structure*, New York: Wiley.
- Spano, J. P., Lagorce, C., Atlan, D., Milano, G., Domont, J., Benamouzig, R., Attar, A., Benichou, J., Martin, A., Morere, J. F., Raphael, M., Penault-Llorca, F., Breau, J. L., Fagard, R., Khayat, D., dan Wind, P., 2005, Impact of EGFR



- expression on colorectal cancer patient prognosis and survival, *Annals of oncology : official journal of the European Society for Medical Oncology*, 16(1), 102–108.
- Suma, A., Wahyuningsih, T.D., dan Mustofa, M., 2019, Synthesis, Cytotoxicity Evaluation and Molecular Docking Study of N-Phenylpirazolin Derivatives, *Indonesian Journal of Chemistry*, 19: 1081.
- Tambunan, U.S. dan Alamudi, S., 2010. Designing cyclic peptide inhibitor of dengue virus NS3-NS2B protease by using molecular docking approach. *Bioinformation*. 5(6):250-254.
- Temel, H.E., Altintop, M.D., dan Özdemir, A., 2018, Synthesis and Evaluation of a New Series of Thiazolyl-pirazolin Derivatives as Cholinesterase Inhibitors, *Turkish Journal of Pharmaceutical Sciences*, 15: 333–338.
- Tong, W., Hong, H., Xie, Q., Shi, L., Fang, H., dan Perkins, R., 2005, Assessing QSAR Limitations – A Regulatory Perspective, *Current Computer-Aided Drug Design*, 1 (2): 195–205.
- Vahedpour, T., Hamzeh-Mivehroud, M., Hemmati, S., dan Dastmalchi, S., 2021, Synthesis of 2-Pirazolins from Hydrazines: Mechanisms Explained, *ChemistrySelect*, 6: 6483–6506.
- Verma, J., Khedkar, V. M., dan Coutinho, E. C., 2010, 3D-QSAR in drug design--a review. *Current topics in medicinal chemistry*, 10(1), 95–115.
- Widodo, I., Dwianingsih, E.K., Aryandono, T., dan Soeripto, S., 2019, Clinicopathological Characteristic and Prognostic Significance of Indonesian Triple Negative Breast Cancer, *The Indonesian Biomedical Journal*, 11: 286–92.
- WHO., 2022, Cancer, <https://www.who.int/news-room/fact-sheets/detail/cancer>, 3 February 2022.
- Yan, M., Xu, L., Wang, Y., Wan, J., Liu, T., Liu, W., Wan, Y., Zhang, B., Wang, R., dan Li, Q., 2020, Opportunities and challenges of using five-membered ring compounds as promising antitubercular agents, *Drug development research*, 81(4), 402–418.
- Yang, B., Yang, Y.S., Yang, N., Li, G., Zhu, H.L., 2016, Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pirazolin turunanives with thiourea skeleton as selective HER-2 inhibitors, *Sci Rep* 6, 27571.
- Yarden, Y. dan Sliwkowski, M.X., 2001, Untangling the ErbB signaling network, *Nature Reviews. Molecular Cell Biology*, 2: 127–137.
- Zamrus, S., Akhtar, M. N., Yeap, S. K., Quah, C. K., Loh, W. S., Alitheen, N. B., Zareen, S., Tajuddin, S. N., Hussin, Y., dan Shah, S., 2018, Design, synthesis and cytotoxic effects of curcuminoids on HeLa, K562, MCF-7 and MDA-MB-231 cancer cell lines. *Chemistry Central journal*, 12(1), 31.
- Zhang, X., Gureasko, J., Shen, K., Cole, P. A., dan Kuriyan, J., 2006, An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor, *Cell*, 125(6), 1137–1149.
- Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., dan Greene, M. I., 2007, ErbB receptors: from oncogenes to targeted cancer therapies, *The Journal of clinical investigation*, 117(8), 2051–2058.